Studies on the MSH2 A636P founder mutation in Ashkenazi Jews have shown a higher risk of CRC and endometrial cancer associated with this variant and led to the proposal of adopting a specific surveillance protocol in the mutation carriers [76]. Here, MSH2 is linked to colorectal carcinoma.